<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578680</url>
  </required_header>
  <id_info>
    <org_study_id>3475-189</org_study_id>
    <secondary_id>2015-003694-15</secondary_id>
    <secondary_id>163421</secondary_id>
    <secondary_id>MK-3475-189</secondary_id>
    <nct_id>NCT02578680</nct_id>
  </id_info>
  <brief_title>Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)</brief_title>
  <official_title>A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an efficacy and safety study of pembrolizumab (MK-3475) combined with
      pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in
      participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who
      have not previously received systemic therapy for advanced disease. Participants will be
      randomly assigned to receive pembrolizumab combined with pemetrexed/platinum (Investigators
      choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of
      cisplatin or carboplatin).

      With Amendment 10 (effective date: 23-Dec-2019), active participants, investigator, and
      sponsor personnel or delegate(s) involved in the treatment administration or clinical
      evaluation of the participants will be unblinded, and all participants in the 'control' arm
      will discontinue saline placebo.

      The primary hypothesis is that pembrolizumab in combination with pemetrexed/platinum
      chemotherapy prolongs Progression-Free Survival (PFS) and Overall Survival (OS) compared to
      pemetrexed/platinum chemotherapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Anticipated">March 5, 2021</completion_date>
  <primary_completion_date type="Actual">November 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging</measure>
    <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</measure>
    <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</measure>
    <time_frame>From time of first documented evidence of CR or PR through database cutoff date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
    <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months); Serious AEs: Up to 90 days after last dose of study treatment, Other AEs: Up to 30 days after last dose of study treatment</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. For participants who switched from the Control group to receiving pembro, AEs that occurred after the first dose of pembro are excluded from this interim analysis, but will be included in the final analysis. The number of participants who experienced an AE is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Any Study Drug Due to an AE</measure>
    <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
    <description>The number of participants who discontinued any randomized study drug due to an AE is presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria</measure>
    <time_frame>Up to 24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">616</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab 200 mg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid 350-1000 μg</intervention_name>
    <description>Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12 1000 μg</intervention_name>
    <description>Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg</intervention_name>
    <description>For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV
             nonsquamous NSCLC.

          -  Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma
             kinase (ALK)-directed therapy is not indicated.

          -  Has measurable disease.

          -  Has not received prior systemic treatment for their advanced/metastatic NSCLC.

          -  Can provide tumor tissue.

          -  Has a life expectancy of at least 3 months.

          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Status.

          -  Has adequate organ function

          -  If female of childbearing potential, is willing to use adequate contraception for the
             course of the study through 120 days after the last dose of study medication or
             through 180 days after last dose of chemotherapeutic agents.

          -  If male with a female partner(s) of child-bearing potential, must agree to use
             adequate contraception starting with the first dose of study medication through 120
             days after the last dose of study medication or through 180 days after last dose of
             chemotherapeutic agents.

        Exclusion Criteria:

          -  Has predominantly squamous cell histology NSCLC.

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks prior to administration of pembrolizumab.

          -  Before the first dose of study medication: a) Has received prior systemic cytotoxic
             chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy
             (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (&lt;3 weeks prior to
             first dose)

          -  Received radiation therapy to the lung that is &gt;30 Gray (Gy) within 6 months of the
             first dose of study medication.

          -  Completed palliative radiotherapy within 7 days of the first dose of study medication.

          -  Is expected to require any other form of antineoplastic therapy while on study.

          -  Received a live-virus vaccination within 30 days of planned start of study medication.

          -  Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal
             obstruction, peritoneal carcinomatosis.

          -  Known history of prior malignancy except if participant has undergone potentially
             curative therapy with no evidence of that disease recurrence for 5 years since
             initiation of that therapy, except for successful definitive resection of basal cell
             carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the
             skin, in situ cervical cancer, or other in situ cancers.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Previously had a severe hypersensitivity reaction to treatment with another monoclonal
             antibody (mAb).

          -  Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.

          -  Has active autoimmune disease that has required systemic treatment in past 2 years.

          -  Is on chronic systemic steroids.

          -  Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs),
             other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for
             long-acting agents, such as piroxicam).

          -  Is unable or unwilling to take folic acid or vitamin B12 supplementation.

          -  Had prior treatment with any other anti-programmed cell death-1 (PD-1), or PD-ligand 1
             (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or
             mechanisms. Has participated in any other pembrolizumab study and has been treated
             with pembrolizumab.

          -  Has an active infection requiring therapy.

          -  Has known history of Human Immunodeficiency Virus (HIV).

          -  Has known active Hepatitis B or C.

          -  Has known psychiatric or substance abuse disorder that would interfere with
             cooperation with the requirements of the trial.

          -  Is a regular user (including &quot;recreational use&quot;) of any illicit drugs or had a recent
             history (within the last year) of substance abuse (including alcohol).

          -  Has symptomatic ascites or pleural effusion.

          -  Has interstitial lung disease or a history of pneumonitis that required oral of IV
             glucocorticoids to assist with management.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children prior to 120
             days after the last dose of study medication or through 180 days after last dose of
             chemotherapeutic agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <results_first_submitted>September 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02578680/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>These interim results are based on a database cutoff date of 08-Nov-2017, at which time 372 participants were ongoing in the study. 67 participants randomized to receiving Control treatment had switched to receiving pembrolizumab monotherapy treatment. These interim results are for randomized treatment only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab</title>
          <description>Participants received pembrolizumab (pembro) 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="405"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Switched to Pembrolizumab</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing in Study</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Analysis Population consisted of all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab</title>
          <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="410"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="9.4"/>
                    <measurement group_id="B2" value="62.8" spread="9.1"/>
                    <measurement group_id="B3" value="63.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="581"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status</title>
          <description>Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS &lt;1% were classified as PD-L1 negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>TPS &lt;1%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TPS ≥1%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platinum Chemotherapy</title>
          <description>Participants were classified according to the type of platinum chemotherapy the Investigator chose for them to receive: Cisplatin or Carboplatin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cisplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carboplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <description>Participants were classified according to their smoking status: Never Smoker or Former/Current Smoker.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former/Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging</title>
        <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.</description>
        <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging</title>
          <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.6" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>Based on Cox regression model with treatment as a covariate stratified by PD-L1 status (≥1% vs. &lt;1%), platinum chemotherapy (cisplatin vs. carboplatin) &amp; smoking status (never vs. former/current). Pembrolizumab=numerator; Control=denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS is presented.</description>
        <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA=Median OS not reached NA=Lower Limit OS not reached NA=Upper Limit OS not reached</measurement>
                    <measurement group_id="O2" value="11.3" lower_limit="8.7" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
            <estimate_desc>Based on Cox regression model with treatment as a covariate stratified by PD-L1 status (≥1% vs. &lt;1%), platinum chemotherapy (cisplatin vs. carboplatin) &amp; smoking status (never vs. former/current). Pembrolizumab=numerator; Control=denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</title>
        <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.</description>
        <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</title>
          <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="42.6" upper_limit="52.5"/>
                    <measurement group_id="O2" value="18.9" lower_limit="13.8" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>H0:Difference in percentages=0 vs H1:Difference in percentages&gt;0</p_value_desc>
            <method>Stratified Miettinen and Nurminen</method>
            <param_type>Difference in Percentage vs. Control</param_type>
            <param_value>28.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.1</ci_lower_limit>
            <ci_upper_limit>35.4</ci_upper_limit>
            <estimate_desc>Miettinen and Nurminen method with treatment as a covariate stratified by PD-L1 status (≥1% vs. &lt;1%), platinum chemotherapy (cisplatin vs. carboplatin) &amp; smoking status (never vs. former/current). Pembrolizumab=numerator; Control=denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</title>
        <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.</description>
        <time_frame>From time of first documented evidence of CR or PR through database cutoff date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
        <population>The analysis population consisted of all randomized participants who experienced a confirmed CR or confirmed PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging</title>
          <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented.</description>
          <population>The analysis population consisted of all randomized participants who experienced a confirmed CR or confirmed PR.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="1.1" upper_limit="18.0"/>
                    <measurement group_id="O2" value="7.8" lower_limit="2.1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. For participants who switched from the Control group to receiving pembro, AEs that occurred after the first dose of pembro are excluded from this interim analysis, but will be included in the final analysis. The number of participants who experienced an AE is presented.</description>
        <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months); Serious AEs: Up to 90 days after last dose of study treatment, Other AEs: Up to 30 days after last dose of study treatment</time_frame>
        <population>The analysis population consisted of all randomized participants who received ≥1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. For participants who switched from the Control group to receiving pembro, AEs that occurred after the first dose of pembro are excluded from this interim analysis, but will be included in the final analysis. The number of participants who experienced an AE is presented.</description>
          <population>The analysis population consisted of all randomized participants who received ≥1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Any Study Drug Due to an AE</title>
        <description>The number of participants who discontinued any randomized study drug due to an AE is presented.</description>
        <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months)</time_frame>
        <population>The analysis population consisted of all randomized participants who received ≥1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Any Study Drug Due to an AE</title>
          <description>The number of participants who discontinued any randomized study drug due to an AE is presented.</description>
          <population>The analysis population consisted of all randomized participants who received ≥1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria</title>
        <time_frame>Up to 24 months</time_frame>
        <posting_date>04/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months); Serious AEs: Up to 90 days after last dose of study drug, Other AEs: Up to 30 days after last dose of study drug</time_frame>
      <desc>Population: All participants receiving ≥1 dose of randomized study drug. Per protocol, progression of cancer under study was not considered an AE unless related to study drug. Therefore, MedDRA preferred terms &quot;Neoplasm progression&quot;, &quot;Malignant neoplasm progression&quot; &amp; &quot;Disease progression&quot; not related to study drug are excluded as AEs. For participants who switched from the Control group to receiving pembro, AEs occurring after 1st pembro dose are excluded from this interim analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab</title>
          <description>Participants received pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembro 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurred, participants may have been able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="405"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="405"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="405"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="405"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intestinal pseudo-obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Mesenteric artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="405"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholangitis sclerosing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bacterial colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>CNS ventriculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="405"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="405"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypertrophic osteoarthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tracheal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Autoimmune nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="405"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="405"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="405"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Skin sensitisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="393" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="227" subjects_affected="178" subjects_at_risk="405"/>
                <counts group_id="E2" events="112" subjects_affected="88" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="405"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="192" subjects_affected="104" subjects_at_risk="405"/>
                <counts group_id="E2" events="91" subjects_affected="48" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="100" subjects_affected="64" subjects_at_risk="405"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="405"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="76" subjects_affected="69" subjects_at_risk="405"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="405"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="199" subjects_affected="139" subjects_at_risk="405"/>
                <counts group_id="E2" events="83" subjects_affected="64" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="156" subjects_affected="115" subjects_at_risk="405"/>
                <counts group_id="E2" events="50" subjects_affected="40" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="405"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="392" subjects_affected="223" subjects_at_risk="405"/>
                <counts group_id="E2" events="180" subjects_affected="101" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="35" subjects_at_risk="405"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="160" subjects_affected="94" subjects_at_risk="405"/>
                <counts group_id="E2" events="66" subjects_affected="43" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="121" subjects_affected="77" subjects_at_risk="405"/>
                <counts group_id="E2" events="80" subjects_affected="49" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="405"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="258" subjects_affected="164" subjects_at_risk="405"/>
                <counts group_id="E2" events="126" subjects_affected="77" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="405"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="106" subjects_affected="78" subjects_at_risk="405"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="97" subjects_affected="74" subjects_at_risk="405"/>
                <counts group_id="E2" events="40" subjects_affected="27" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="405"/>
                <counts group_id="E2" events="31" subjects_affected="17" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="405"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="405"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="405"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="62" subjects_affected="49" subjects_at_risk="405"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="38" subjects_at_risk="405"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="69" subjects_affected="46" subjects_at_risk="405"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="37" subjects_at_risk="405"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="26" subjects_at_risk="405"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="149" subjects_affected="114" subjects_at_risk="405"/>
                <counts group_id="E2" events="79" subjects_affected="61" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="27" subjects_at_risk="405"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="43" subjects_at_risk="405"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="31" subjects_at_risk="405"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="33" subjects_at_risk="405"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="61" subjects_affected="52" subjects_at_risk="405"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="405"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="405"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="48" subjects_affected="45" subjects_at_risk="405"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="405"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="57" subjects_affected="48" subjects_at_risk="405"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="405"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="405"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="112" subjects_affected="87" subjects_at_risk="405"/>
                <counts group_id="E2" events="63" subjects_affected="57" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="98" subjects_affected="82" subjects_at_risk="405"/>
                <counts group_id="E2" events="57" subjects_affected="47" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="405"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="405"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="405"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="405"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="405"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="55" subjects_affected="43" subjects_at_risk="405"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="108" subjects_affected="81" subjects_at_risk="405"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

